Back

Defence Therapeutics advances Accum® cancer drug-delivery technology under new CEO

Verifying
  • Defence Therapeutics announced strategic updates under new CEO Dr. Amie Phinney.
  • The company is advancing its proprietary Accum® drug-delivery technology for cancer treatments.
  • Defence Therapeutics plans to develop partnerships involving the technology.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.